Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
West Pharmaceutical Services arrives at its October 29 earnings date with two weeks to go, a Street that keeps revising up, and short sellers who spent the past month heading for the exit.
The analyst story has moved again since last week's note. TD Cowen raised its target to $420 from $410 on October 13, maintaining a Buy. That follows Barclays lifting to $440 from $400 on October 7, and Morgan Stanley's upgrade to Overweight on September 22. Every recent change on the record is a raise or an upgrade. The mean target now sits at $412.88, roughly 11% above the $371.82 close. The analyst recommendation factor ranks in the 92nd percentile of the ORTEX universe. The bull case rests on a company that has beaten estimates consistently, ranking near the 60th percentile on EPS surprise and with 90-day EPS momentum in the 68th percentile. The valuation is the honest objection: the trailing PE is 38x and EV/EBITDA is 25x, with the EV/EBIT factor scoring in just the 23rd percentile. BNP Paribas initiated in July with an Outperform and a $447 target, the most optimistic on the Street, while the Morgan Stanley upgrade was accompanied by a $400 target that already sits below the current consensus.
Short positioning has eased materially over the past month, and the borrow market confirms there is no pressure building. Short interest has fallen to 2.9% of the free float, down about 8% on the week and 5% over the past month. Shares short peaked near the mid-September highs and have been drifting lower since. Cost to borrow, at 0.37%, is among the cheapest it has been in recent weeks, and borrow availability is extremely loose, with an availability reading of over 6,000%, meaning there is far more lending supply than demand. The ORTEX short score, at 34.8, is the lowest it has been in the past two weeks, consistent with bears retreating rather than pressing. Options positioning is also relaxed: the put/call ratio of 0.73 is marginally below its 20-day average, and nowhere near the 52-week high of 2.48 that captured a genuinely defensive moment earlier in the year.
Retail attention has ticked up. Wikipedia page views are running 1.6 standard deviations above their own 90-day baseline, a measure of awareness rather than a financial signal. With earnings 15 days out, that uptick is not unusual for a stock that has gained roughly 7% over the past month.
The most notable ownership development is in the institutional register. FMR (Fidelity) added 2.3 million shares in the most recent filing period, lifting its position to 5% of shares outstanding, enough to trigger a Schedule 13G filing in August. BlackRock remains the largest holder at 9.5% of shares. All 13D/G positions are passive, with no activist on the register. Insider activity in September was entirely composed of option exercises and pre-arranged sales under 10b5-1 plans by the Chief HR Officer, which carry limited signal by their nature.
The last earnings print on July 23 produced a one-day decline of 8.4% and a five-day move of minus 5.3%, making it the clearest data point on how the stock reacts when results disappoint. The prior event on July 30 produced a gain of 1%. With the Street uniformly constructive and shorts having largely stood down, what to watch on October 29 is how the company's commentary on volume trends and margin recovery squares with a valuation that already prices in a meaningful recovery.
See the live data behind this article on ORTEX.
Open WST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
